End-of-day quote
Egyptian Exchange
23:00:00 19/05/2024 BST
|
5-day change
|
1st Jan Change
|
36.72
EGP
|
+2.48%
|
|
+9.61%
|
+0.60%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
6,592
|
4,309
|
4,155
|
3,621
|
5,430
|
5,462
|
-
|
-
|
Enterprise Value (EV)
1 |
6,592
|
5,356
|
5,592
|
5,985
|
9,634
|
11,992
|
12,073
|
12,021
|
P/E ratio
|
9.83
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Yield
|
-
|
6.79%
|
3.58%
|
-
|
-
|
6.81%
|
8.17%
|
-
|
Capitalization / Revenue
|
1.93
x
|
1.48
x
|
1.21
x
|
0.92
x
|
1.04
x
|
0.77
x
|
0.65
x
|
0.56
x
|
EV / Revenue
|
1.93
x
|
1.84
x
|
1.63
x
|
1.51
x
|
1.84
x
|
1.69
x
|
1.44
x
|
1.23
x
|
EV / EBITDA
|
7.53
x
|
6.8
x
|
5.57
x
|
6.85
x
|
6.56
x
|
6.01
x
|
5.06
x
|
4.31
x
|
EV / FCF
|
63.9
x
|
-138
x
|
-105
x
|
-6.35
x
|
-4.38
x
|
36.3
x
|
11.2
x
|
9.93
x
|
FCF Yield
|
1.57%
|
-0.72%
|
-0.95%
|
-15.8%
|
-22.8%
|
2.75%
|
8.96%
|
10.1%
|
Price to Book
|
2.23
x
|
1.49
x
|
1.46
x
|
1.12
x
|
1.28
x
|
1.26
x
|
1.13
x
|
-
|
Nbr of stocks (in thousands)
|
99,171
|
99,171
|
99,171
|
99,171
|
148,756
|
148,756
|
-
|
-
|
Reference price
2 |
66.47
|
43.45
|
41.90
|
36.51
|
36.50
|
36.72
|
36.72
|
36.72
|
Announcement Date
|
27/02/20
|
25/02/21
|
23/02/22
|
01/03/23
|
01/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
3,411
|
2,910
|
3,437
|
3,955
|
5,232
|
7,103
|
8,412
|
9,780
|
EBITDA
1 |
875.7
|
787.2
|
1,004
|
874.2
|
1,469
|
1,996
|
2,385
|
2,786
|
EBIT
1 |
728.9
|
647.6
|
894.8
|
774.9
|
1,364
|
1,813
|
2,167
|
-
|
Operating Margin
|
21.37%
|
22.26%
|
26.04%
|
19.59%
|
26.08%
|
25.52%
|
25.76%
|
-
|
Earnings before Tax (EBT)
1 |
840.6
|
595.3
|
688.7
|
804.7
|
1,083
|
1,129
|
1,402
|
-
|
Net income
1 |
670.6
|
486.5
|
522.8
|
643.8
|
823.3
|
874
|
1,085
|
-
|
Net margin
|
19.66%
|
16.72%
|
15.21%
|
16.28%
|
15.74%
|
12.3%
|
12.9%
|
-
|
EPS
|
6.762
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
103.2
|
-38.7
|
-53.27
|
-943
|
-2,200
|
330
|
1,082
|
1,211
|
FCF margin
|
3.03%
|
-1.33%
|
-1.55%
|
-23.84%
|
-42.05%
|
4.65%
|
12.86%
|
12.38%
|
FCF Conversion (EBITDA)
|
11.78%
|
-
|
-
|
-
|
-
|
16.53%
|
45.37%
|
43.47%
|
FCF Conversion (Net income)
|
15.39%
|
-
|
-
|
-
|
-
|
37.76%
|
99.72%
|
-
|
Dividend per Share
2 |
-
|
2.950
|
1.500
|
-
|
-
|
2.500
|
3.000
|
-
|
Announcement Date
|
27/02/20
|
25/02/21
|
23/02/22
|
01/03/23
|
01/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2023 Q4
|
---|
Net sales
1 |
899.3
|
1,551
|
EBITDA
1 |
-
|
377.6
|
EBIT
|
-
|
-
|
Operating Margin
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
Net income
|
-
|
-
|
Net margin
|
-
|
-
|
EPS
|
-
|
-
|
Dividend per Share
|
-
|
-
|
Announcement Date
|
07/11/21
|
01/03/24
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
1,047
|
1,437
|
2,364
|
4,204
|
6,530
|
6,611
|
6,559
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
1.33
x
|
1.431
x
|
2.704
x
|
2.861
x
|
3.272
x
|
2.772
x
|
2.354
x
|
Free Cash Flow
1 |
103
|
-38.7
|
-53.3
|
-943
|
-2,200
|
330
|
1,082
|
1,211
|
ROE (net income / shareholders' equity)
|
23.4%
|
16.8%
|
18%
|
20%
|
22%
|
19.1%
|
21.3%
|
25%
|
ROA (Net income/ Total Assets)
|
16.2%
|
10.3%
|
10.1%
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
4,143
|
4,724
|
5,153
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
29.70
|
29.10
|
28.70
|
32.70
|
28.60
|
29.10
|
32.60
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
177
|
204
|
437
|
562
|
2,290
|
800
|
271
|
315
|
Capex / Sales
|
5.19%
|
7%
|
12.72%
|
14.21%
|
43.78%
|
11.26%
|
3.22%
|
3.22%
|
Announcement Date
|
27/02/20
|
25/02/21
|
23/02/22
|
01/03/23
|
01/03/24
|
-
|
-
|
-
|
Last Close Price
36.72
EGP Average target price
75.3
EGP Spread / Average Target +105.07% Consensus |
1st Jan change
|
Capi.
|
---|
| +0.60% | 117M | | +22.35% | 44.12B | | +22.22% | 22.61B | | +17.04% | 15.11B | | +15.73% | 13.61B | | +57.91% | 13.34B | | -8.98% | 6.94B | | -0.05% | 6.79B | | +15.65% | 5.75B | | -8.87% | 5.73B |
Generic Pharmaceuticals
|